Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06PEW
|
|||
| Former ID |
DIB007800
|
|||
| Drug Name |
IT-101
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 3 | [1] | |
| Company |
Insert Therapeutics
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00163319) Efficacy of Ciclesonide and Fluticasone Propionate in Adult Patients With Moderate and Severe Persistent Asthma (18 to 75 y) (BY9010/IT-101). U.S. National Institutesof Health. | |||
| REF 2 | CRLX101, an investigational camptothecin-containing nanoparticle-drug conjugate, targets cancer stem cells and impedes resistance to antiangiogenic therapy in mouse models of breast cancer. Breast Cancer Res Treat. 2015 Apr;150(3):559-67. | |||
| REF 3 | CRLX101 (formerly IT-101)-A Novel Nanopharmaceutical of Camptothecin in Clinical Development. Curr Bioact Compd. 2011 March; 7(1): 8-14. | |||
| REF 4 | Preclinical to clinical development of the novel camptothecin nanopharmaceutical CRLX101. J Control Release. 2011 Jul 15;153(1):49-55. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.